0.13
3.42%
-0.0046
Avenue Therapeutics Inc stock is currently priced at $0.13, with a 24-hour trading volume of 320.64K.
It has seen a -3.42% decreased in the last 24 hours and a -18.75% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1343 pivot point. If it approaches the $0.128 support level, significant changes may occur.
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Avenue Therapeutics Inc (ATXI) Net Income 2024
ATXI net income (TTM) was -$10.38 million for the quarter ending December 31, 2023, a -192.15% decrease year-over-year.
Avenue Therapeutics Inc (ATXI) Cash Flow 2024
ATXI recorded a free cash flow (TTM) of -$12.45 million for the quarter ending December 31, 2023, a -63.92% decrease year-over-year.
Avenue Therapeutics Inc (ATXI) Earnings per Share 2024
ATXI earnings per share (TTM) was -$3.81 for the quarter ending December 31, 2023, a -36.58% decline year-over-year.
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
GlobeNewswire Inc.
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
GlobeNewswire Inc.
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
GlobeNewswire Inc.
About Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Cap:
|
Volume (24h):